Molecular pathology of endometrial carcinoma
Top Cited Papers
- 13 December 2012
- journal article
- review article
- Published by Wiley in Histopathology
- Vol. 62 (1), 111-123
- https://doi.org/10.1111/his.12053
Abstract
This review paper discusses the main molecular alterations of endometrial carcinoma, the most common cancer of the female genital tract. Two clinicopathological variants are recognized: the oestrogen-related (type I, endometrioid carcinoma) and the non-oestrogen-related (type II, non-endometrioid carcinoma). Whereas type I shows microsatellite instability and mutations in PTEN, PIK3CA, K-RAS and CTNNB1 (beta-catenin), type II exhibits TP53 mutations and chromosomal instability. Recent investigations regarding the role of non-coding RNA have provided important information regarding tumour progression. Understanding pathogenesis at the molecular level is essential for identifying biomarkers of potential use in targeted therapies.Keywords
This publication has 64 references indexed in Scilit:
- PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial CancerCancer Research, 2011
- Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid CarcinomaThe American Journal of Surgical Pathology, 2011
- KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP LevelsThe American Journal of Pathology, 2011
- A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial CarcinomasClinical Cancer Research, 2011
- MicroRNA signatures differentiate uterine cancer tumor subtypesGynecologic Oncology, 2010
- A coding-independent function of gene and pseudogene mRNAs regulates tumour biologyNature, 2010
- Molecular alterations of EGFR and PIK3CA in uterine serous carcinomaGynecologic Oncology, 2009
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K MutationsCancer Research, 2008
- Drug-sensitiveFGFR2mutations in endometrial carcinomaProceedings of the National Academy of Sciences, 2008
- Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene, 2007